Clinical Trials in Georgia

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies

A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Cancer Type: Unspecified

A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Combination with Alnuctamab, Mezigdomide, or Iberdomide in Participants with Relapsed and/or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Phase Ia/Ib Study of NMS-03597812 in Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia including patients with TP53 mutations
Cancer Type: Unspecified

A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies
Cancer Type: Hematopoietic Malignancies

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Cancer Type: Unknown Primary

A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Cancer Type: Hematopoietic Malignancies

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Cancer Type: Multiple Myeloma

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

Autologous CD19/CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Cancer Type: Unknown Primary

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Cancer Type: Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Cancer Type: Non-Hodgkin Lymphoma

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL
Cancer Type: Cancer-Related Syndrome

Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2
Cancer Type: Unspecified

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
Cancer Type: Graft Versus Host Disease

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Cancer Type: Lymphoma

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Cancer Type: Leukemia, Lymphoma

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

Long-term Follow-up Study of Allogeneic Gamma Delta (?d) CAR T Cells
Cancer Type: Lymphoma, Non-Hodgkin Lymphoma

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide
Cancer Type: Hematopoietic Malignancies

Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Cancer Type: Graft Versus Host Disease

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation for the Treatment of Blood Cancer in Patients Undergoing Donor Stem Cell Transplant
Cancer Type: Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Cancer Type: Leukemia

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
Cancer Type: Solid Tumor

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Cancer Type: Multiple Myeloma

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Cancer Type: Leukemia, Multiple Myeloma

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Cancer Type: Unspecified

Testing the Addition of a New Drug, Daratumumab/rHuPH20, to the Usual Treatment (Lenalidomide) as Post-stem Cell Transplant Treatment for Multiple Myeloma, DRAMMATIC Study
Cancer Type: Multiple Myeloma, Plasma cell neoplasm